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Abstract
Background: Pulmonary adenoid cystic carcinoma (PACC) is an uncommon neoplasm of the lung but represents
the predominant type of salivary gland-type lung carcinoma. Only a few studies have focused on the genetic
events associated with PACC. The aim of this study was to characterize the genetic events associated with PACC.
Findings: We reviewed 24 cases of primary PACC between 2000 and 2014, including 21 cases reported in our
previous study and three new cases added in 2014. Mutation profiling of the EGFR, KRAS, BRAF, ALK, PIK3CA,
PDGFRA, and DDR2 genes was performed using next-generation sequencing, Sanger sequencing, and quantitative
polymerase chain reaction in 9 successfully amplified cases. The 24 cases of PACC included 7 men and 17 women,
aged 24–74 years (mean, 50.8 years). All the cases were located in the trachea or bronchus. No mutations were
detected in any of the seven genes in the nine cases that qualified for mutation analysis, and the results using
different methods were consistent.
Conclusions: The data presented in this work suggest that EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 may
not be driver genes in primary pulmonary adenoid cystic carcinoma.
Findings
Introduction
Primary pulmonary adenoid cystic carcinoma (PACC) is
a rare neoplasm. It is presumed to originate from the
minor salivary glands lining the tracheobronchial tree
and is one of the main types of salivary gland-type
carcinoma of the lung [1]. Although many molecular
genetic studies have implicated certain genetic mutations
in non-small cell lung cancer (NSCLC), including muta-
tions in the EGFR, PIK3CA, BRAF, KRAS, and ALK
genes [2, 3], only a few studies have focused on the
genetic events associated with salivary gland-type lung
carcinomas. With the exception of the recent discovery
of translocations and fusion oncogenes in salivary gland
tumours, a few studies have reported that genetic alter-
ations in genes such as EGFR, KIT, BRAF, CCND1,
HRAS, KRAS, NRAS, PIK3CA, and PDGFRA occur in
malignant salivary gland tumours at a lower frequency
[4–16]. Gene alterations in KIT, EGFR, BRAF, HRAS,
KRAS, NRAS, PIK3CA, PDGFRA, and PTEN have been
reported in adenoid cystic carcinoma (ACC) [4, 5, 7–16],
but the results are inconsistent among different studies
[10, 12, 17]. The genetic studies of PACC are scarce, and
no genetic alterations, such as in EGFR and KIT, have
been detected in these studies [18, 19]. In the current
study, we reviewed a retrospective series of 24 patients
with primary PACC and evaluated the EGFR, KRAS,
BRAF, ALK, PIK3CA, PDGFRA, and DDR2 gene status
using three different methods, including next-generation
sequencing (NGS), Sanger sequencing, and quantitative
polymerase chain reaction (QPCR).
Materials and methods
Patients and specimens
We reviewed all the surgical lung biopsy or resection
records at Peking Union Medical College Hospital from
2000 to 2014 and identified a total of 24 cases of PACC,
including 21 cases reported in our previous study [20]
and three new cases added in 2014. No patient had a
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history of a salivary gland tumour. All the samples were
fixed in 10 % neutral buffered formalin, routinely proc-
essed, and embedded in paraffin. Haematoxylin-eosin-
stained sections were observed by optical microscopy and
reviewed independently by three experienced pathologists
based on the World Health Organization criteria for
PACC [1]. The ethics committee of Peking Union Medical
Collage Hospital specifically approved this study, and
informed consent was obtained from all patients.
Genomic DNA from 21 PACC samples with sufficient
available tissue was extracted from freshly cut formalin-
fixed, paraffin-embedded tissue sections using a QIAamp
DNA Mini Kit (Qiagen, Germany) according to the manu-
facturer’s instructions. The tumour area was identified
through haematoxylin-eosin staining, and tissue from this
area on unstained sections was removed for DNA extrac-
tion. The extracted DNA was then quantified using the
Qubit dsDNA BR Assay (Life Technologies, USA). Out of
21 cases of PACC, DNA from nine cases was successfully
amplified. Mutational analysis was performed using three
different methods, including NGS, Sanger sequencing,
and QPCR.
NGS and data processing
Targeted NGS was performed with 10 ng of DNA as the
template to generate the amplicon library for sequen-
cing. Libraries were prepared using the Ion AmpliSeq
Library Kit 2.0 (Life Technologies, USA) and the Lung
Cancer Mutation Panel (ACCB Biotech, China), which is
designed to detect mutations within 16 exons of seven
lung cancer driver genes (EGFR, KRAS, BRAF, ALK,
PIK3CA, PDGFRA, and DDR2) (Table 1). Adapter
ligation, nick repair, and PCR amplification were per-
formed according to the manufacturer’s protocol. Libraries
were then quantified using a Qubit dsDNA HS Assay Kit
and a Qubit 2.0 fluorometer (Life Technologies, USA),
with samples diluted to a concentration of 3 ng/mL and
pooled in equal volumes. Emulsion PCR and enrichment
steps were performed using an Ion OneTouch Template
Kit on the Ion OneTouch system (Life Technologies,
USA) according to the manufacturer’s protocol. After
enrichment, the amplicon libraries were subjected to
sequencing on the Ion Torrent PGM system (Life Tech-
nologies, USA) using 318 chips and barcoding with the
Ion Xpress Barcode Adapters 1–16 Kit (Life Technologies,
USA). After sequencing, reads were mapped to the
reference genome (hg19) using the Torrent Mapping
Alignment Program (TMAP). Variants were identified
using Torrent Variant Caller (version 3.6.6; Life Techno-
logies, USA). The Integrative Genomics Viewer (Broad
Institute, USA) was used to visualize variants against the
reference genome to confirm the accuracy of the variant
calls by checking for possible strand biases and sequen-
cing errors.
Sanger sequencing
Mutations within 16 exons of the seven lung cancer
driver genes were also screened by PCR-based bidir-
ectional direct Sanger sequencing using primers. The
sequencing results were interpreted using Chromas
software version 1.45 (Technelysium Pty, Australia).
QPCR
The Human Mutation Qualitative Detection Kit (ACCB
Biotech, China) was used according to the manufacturer’s
instructions. QPCR was performed on a Rotor-Gene
QPCR Platform (Qiagen, Germany). The cycling condi-
tions for quality control (QC) runs and for mutation assays
were as follows: 10 min at 95 °C followed by 40 cycles of
95 °C for 15 s and 60 °C for 1 min. Fluorescence was
measured at 60 °C. Data regarding each mutation
were interpreted according to the kit manual after
curve analysis and calculation of ΔCt values.
Results
The 24 cases of PACC included 7 men and 17 women,
with a mean age of 50.8 years, and accounted for 0.23 %
of all 10500 cases of primary histologically diagnosed
malignant pulmonary tumours. Five patients had a his-
tory of smoking. Cough, dyspnea, and haemoptysis were
the most common symptoms. All 24 primary cases were
located in the trachea or bronchus, and they all exhib-
ited typical PACC histopathology. Follow-up data (range,
1–132 months) was available for 18 patients, one patient
died of a surgical complication, and five patients expe-
rienced disease recurrence and/or metastasis. No muta-
tions were found within 16 exons of the EGFR, KRAS,
BRAF, ALK, PIK3CA, PDGFRA, and DDR2 genes using
NGS, Sanger sequencing, and QPCR in 9 successfully
amplified cases (Table 2, Figs. 1, 2, 3). The results using
the three methods were consistent.
Discussion
Primary salivary gland-type tumours of the lung are rare
[1] and differ from the more common types of lung
Table 1 The 16 exons of the seven genes analysed in the
present study
Genes Exons
EGFR Exons 18, 19, 20 and 21
KRAS Exons 2 and 3
BRAF Exons 11 and 15
PIK3CA Exons 9 and 20
ALK Exons 23 and 25
DDR2 Exon 18
PDGFRA Exons 12, 14 and 18
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cancer. As the main type of salivary gland-type lung
carcinoma, PACC is difficult to diagnose and cure at the
early stage and is unlikely to be completely surgically
removed. Postoperative radiotherapy is helpful for redu-
cing the likelihood of recurrence and metastasis [20].
However, only limited data are available on the role of
conventional systemic and targeted therapies in the
management of patients with advanced disease. There is
perhaps a need to develop new molecular biomarkers to
improve the therapeutic options for these patients.
Recently, important advances have been made in ACC; a
signature t(6;9)(q22–23; p23–24) chromosomal trans-
location resulting in a MYB–NFIB fusion gene was identi-
fied, and the fusion oncoprotein activates the transcription
of MYB targets that are important for oncogenic trans-
formation. An increasing number of studies has demon-
strated that MYB activation occurs in more than 80 % of
cases of ACC, including PACC [4]. In this study, we aimed
to identify driver genes other than MYB in PACC.
Genetic alterations associated with the development of
NSCLC have been extensively characterized. The driver
genes involved in lung adenocarcinoma include KRAS,
EGFR, ALK, and BRAF [2], and those implicated in lung
squamous cell carcinoma (LSCC) include PIK3CA,
FGFR1, EGFR, PDGFRA, and DDR2 [3]. However, the
mutational status of these genes in PACC has not been
well characterized. Activating mutations in EGFR identify
those NSCLC patients with an improved clinical response
to tyrosine kinase inhibitor (TKI) therapy, but it remains
unknown whether patients with PACC harbour EGFR
mutations and can thus benefit from TKI therapy. EGFR
mutations have been reported in pulmonary and salivary
mucoepidermoid carcinoma [21], but they are rare in
ACC of the salivary gland [14, 15], and no EGFR muta-
tions were detected in PACC in a previous study [18].
Similarly, in our series, no mutations in EGFR were de-
tected. A few studies have identified alterations in KRAS
in ACC [7, 12, 13], and KRAS alterations were reported to
Table 2 Clinical and genetic data for the 9 successfully amplified cases with PACC
No. Age
(y)
Gender Location Genetic mutation
EGFR KRAS BRAF PIK3CA ALK DDR2 PDGFRA
1 38 M Trachea (upper 1/3) - - - - - - -
2 56 F Trachea (upper 1/3) - - - - - - -
3 35 F Trachea (lower 1/3) - - - - - - -
4 60 F Trachea (lower 1/3) - - - - - - -
5 51 F Trachea (lower 1/3) - - - - - - -
6 57 F Trachea (upper 1/3) - - - - - - -
7 62 F Trachea (middle 1/3) - - - - - - -
8 74 F Trachea (upper 1/3) - - - - - - -
9 46 F Trachea (lower 1/3) - - - - - - -
Fig. 1 No mutations were found in PACC cases by NGS. a No L858R mutations were found in EGFR. b No G12D mutations were found in KRAS
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be more common than other gene alterations, with the
exception of MYB, in a recent study [12]; however, KRAS
mutations were absent in other studies that involved whole
exome sequencing of ACC [16] and next-generation
sequencing [15]. There are no relevant studies on KRAS in
PACC in the literature, and KRAS mutations were not
detected in our series. Genetic alterations in PIK3CA
[8, 11, 15, 16] and BRAF [10, 13] have been detected
in ACC at a lower frequency than KRAS, and a study sug-
gested that the PI3K/AKT pathway may be responsible for
the unusually aggressive course of ACC [8]. There are no
similar relevant studies in PACC, and no PIK3CA and
BRAF gene mutations were detected in our series. ALK
gene alterations mainly occur in lung adenocarcinoma
and are associated with gene rearrangements. ALK in-
hibitors exhibit marked anti-tumour activity against
lung cancers with ALK rearrangements [22]. However,
emerging genomic data are revealing common ALK
point mutations in various cancer types other than
lung cancer, and several recent studies have demonstrated
that ALK point mutations, independent of ALK gene
rearrangements, can be oncogenic [23]. Genetic alter-
ations of DDR2 and PDGFRA are associated with the de-
velopment of LSCC [3, 24, 25]. Recently, DDR2 mutations
were reported in approximately 4 % of LSCC cases, and
some of these mutations induced oncogenic transform-
ation. DDR2 mutations are associated with increased
sensitivity to dasatinib, and the clinical activity of dasa-
tinib in lung cancer is being evaluated in numerous
clinical trials [24]. Platelet-derived growth factor recep-
tors (PDGFRs) and their ligands play critical roles in
several human malignancies. Sunitinib is a clinically
approved, multi-targeted TKI that inhibits PDGFR with
demonstrated clinical activity in gastrointestinal stro-
mal tumours. However, some rare tumours, including
LSCC, that demonstrate PDGFRA activation may also
be clinically responsive to pharmacologic PDGFRA
inhibition [25]. However, alterations in the ALK and
DDR2 genes have not yet been investigated in ACC,
and PDGFRA was only detected in two ACC cases [15].
In our series, there were no mutations in the ALK,
DDR2, and PDGFRA genes. Our study suggested that
Fig. 2 No mutations were found in PACC by QPCR (the same case as in Fig. 1). a No L858R mutations were found in EGFR. b No G12D mutations
were found in KRAS
Fig. 3 No mutations were found in PACC by Sanger sequencing (the same case as in Fig. 1). a No L858R mutations were found in EGFR. b No
G12D mutations were found in KRAS
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the genetic mutations associated with PACC are different
from those implicated in NSCLC, and EGFR, KRAS,
BRAF, ALK, PIK3CA, PDGFRA, and DDR2 might not be
driver genes in PACC.
The results of the present study are important in that
they indicate that the targeted gene therapies for NSCLC
may be useless in patients with PACC because of the
different gene profiles. Our study has some limitations.
First, the number of samples in the study was relatively
small because of the low incidence of PACC and the lim-
ited success in extracting DNA for amplification over a
long time span of 15 years. Second, only seven genes were
analysed using three methods. We will expand the scope
of the genes and increase the number of cases by involving
other institutions in our future study of PACC to identify
other genes for targeted therapy against PACC. Interest-
ingly, we performed mutation profiling using three
methods, including NGS, Sanger sequencing, and QPCR,
and the results were consistent. Although the gold stand-
ard methods for detecting gene mutations are Sanger
sequencing and QPCR, we believe that NGS is as good as
the other methods because similar results were obtained
in our study and because NGS saves time and uses less
sample tissue. To date, only one study on ACC has used
NGS technology [15]; our study is the second to analyse
genetic mutations in ACC using NGS methodology.
In conclusion, the genetic mutations associated with
PACC are different from those implicated in non-small
cell lung cancer, and EGFR, KRAS, BRAF, ALK,
PIK3CA, PDGFRA, and DDR2 may not be driver genes
in PACC; we must identify other genes for targeted therapy
against PACC.
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